Metraipolis › archive › dc_ae87cf7c3286

Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms — Europe PMC PMID:41865008

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41865008
DOI
10.1186/s13195-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-11-04T03:35:52.032Z
SHA-256 of the archived text
107d52acbd6aaed1d2e4f101a2d30d26bf8342291504c0ab3ae0fa8755378207
Stable URL of this page
https://metraipolis.com/documento/dc_ae87cf7c3286

How to cite

Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms — Europe PMC PMID:41865008 — Europe PMC (en), https://europepmc.org/article/MED/41865008 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae87cf7c3286 (Metraipolis archive dc_ae87cf7c3286, sha256 107d52acbd6aaed1d2e4f101a2d30d26bf8342291504c0ab3ae0fa8755378207)
BibTeX
@misc{dcae87cf7c3286,
  title = {Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms — Europe PMC PMID:41865008},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41865008},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae87cf7c3286; sha256 107d52acbd6aaed1d2e4f101a2d30d26bf8342291504c0ab3ae0fa8755378207},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41865008. Agents can read the archived copy with the MCP tool read_document.